Exclusive: Vertex founder Joshua Boger joins tiny Boston biotech as chair, ahead of mid-stage readout for dementia drug

Since end­ing a two-decade tenure as Ver­tex Phar­ma­ceu­ti­cals’ CEO in 2009, Joshua Boger has had no lack of op­por­tu­ni­ties to jump on biotech boards.

He’s said no to vir­tu­al­ly every of­fer — ex­cept this one. Boger ex­clu­sive­ly told End­points News he will join Cer­voMed as its chair. It’s the sec­ond biotech board seat Boger has tak­en on af­ter Ver­tex, along­side his ex­ec­u­tive chair role at Alkeus Phar­ma­ceu­ti­cals, which is de­vel­op­ing a drug for Star­gardt dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.